14 Mar 2012 07:00
14 March 2012
LSE: VER
Notice of Results for the Twelve Months Ended 31 December 2011
Vernalis plc today announces its year end results for the twelve months ended 31 December 2011 will be released on Tuesday, 3 April 2012. The earnings announcement will be distributed at 7:00 am (UK) and will be available to download from www.vernalis.com.
Following the results announcement, the Company will host an analyst presentation and concurrent conference call at 9:00 am (UK) on 3 April 2012. The presentation will be held at the offices of Brunswick Group, 16 Lincoln's Inn Fields, London, WC2A 3ED. Please contact Valerie Mugridge at Brunswick on +44 (0) 207 396 5325 if you plan to attend in person.
-- ends --
Enquiries:
Vernalis Contacts
| |
Ian Garland, Chief Executive Officer | +44 (0) 118 989 9360 |
David Mackney, Chief Financial Officer
| |
Brunswick Group
| |
Jon Coles | +44 (0) 20 7404 5959 |
Kristin Shine
| |
Taylor Rafferty
| |
Rob Newman | +44 (0) 20 7614 2900 |
Faisal Kanth |
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, GSK, Lundbeck, Menarini, Novartis and Servier.
Product | Indication | Pre-Clinical | Phase I | Phase II | Phase III | Marketed | Marketing Rights |
PRIORITY PROGRAMMES | |||||||
CNS Programmes | |||||||
Frovatriptan | Acute Migraine | X | Menarini & Endo Pharma | ||||
V158866 | Pain | X | Worldwide | ||||
V81444 | Parkinson's Disease | X | Worldwide | ||||
Oncology Programmes | |||||||
AUY922 | Cancer | X | Novartis | ||||
CHR2797 | Cancer | X | Chroma Therapeutics | ||||
HSP990 | Cancer | X | Novartis | ||||
V158411 | Cancer | X | Worldwide | ||||
Other Therapeutic Areas | |||||||
V85546 | Inflammatory Disease | X | Worldwide | ||||
LEGACY PROGRAMMES | |||||||
RPL554 | Asthma/ Allergic Rhinitis | X | Verona Pharma | ||||
For further information about Vernalis, please visit www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.